TY - JOUR
T1 - Brevinin-1BYa
T2 - a naturally occurring peptide from frog skin with broad-spectrum antibacterial and antifungal properties
AU - Pál, Tibor
AU - Abraham, Bency
AU - Sonnevend, Ágnes
AU - Jumaa, Pauline
AU - Conlon, J. Michael
PY - 2006/6
Y1 - 2006/6
N2 - Brevinin-1BYa (FLPILASLAAKFGPKLFCLVTKKC) is a cationic α-helical peptide containing an intramolecular disulphide bridge that is present in skin secretions of the foothill yellow-legged frog Rana boylii. A synthetic replicate of the peptide showed growth inhibitory activity against a range of reference strains of Gram-positive and Gram-negative bacteria, against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) (minimum inhibitory concentration (MIC) = 2.5 μM), and against reference strains and clinical isolates of the opportunistic yeast pathogens Candida albicans, Candida tropicalis, Candida krusei and Candida parapsilosis (MIC ≤ 10 μM). However, the therapeutic potential of the peptide, especially for systemic applications, is restricted by its high haemolytic activity against human erythrocytes (LD50 = 10 μM). Replacement of the cysteine residues in brevinin-1BYa by serine produced an acyclic analogue with eight-fold reduced haemolytic activity that retained high potency against Gram-positive bacteria, including strains of MRSA (MIC = 5 μM), however activities against Gram-negative bacteria and yeast species were reduced. It is suggested that brevinin-1BYa represents a candidate for drug development, particularly for topical applications against antibiotic-resistant microorganisms.
AB - Brevinin-1BYa (FLPILASLAAKFGPKLFCLVTKKC) is a cationic α-helical peptide containing an intramolecular disulphide bridge that is present in skin secretions of the foothill yellow-legged frog Rana boylii. A synthetic replicate of the peptide showed growth inhibitory activity against a range of reference strains of Gram-positive and Gram-negative bacteria, against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) (minimum inhibitory concentration (MIC) = 2.5 μM), and against reference strains and clinical isolates of the opportunistic yeast pathogens Candida albicans, Candida tropicalis, Candida krusei and Candida parapsilosis (MIC ≤ 10 μM). However, the therapeutic potential of the peptide, especially for systemic applications, is restricted by its high haemolytic activity against human erythrocytes (LD50 = 10 μM). Replacement of the cysteine residues in brevinin-1BYa by serine produced an acyclic analogue with eight-fold reduced haemolytic activity that retained high potency against Gram-positive bacteria, including strains of MRSA (MIC = 5 μM), however activities against Gram-negative bacteria and yeast species were reduced. It is suggested that brevinin-1BYa represents a candidate for drug development, particularly for topical applications against antibiotic-resistant microorganisms.
KW - Antibacterial and antifungal peptide
KW - Brevinin-1
KW - Frog skin
UR - http://www.scopus.com/inward/record.url?scp=33646756145&partnerID=8YFLogxK
U2 - 10.1016/j.ijantimicag.2006.01.010
DO - 10.1016/j.ijantimicag.2006.01.010
M3 - Article
C2 - 16713189
AN - SCOPUS:33646756145
SN - 0924-8579
VL - 27
SP - 525
EP - 529
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
IS - 6
ER -